How Much Does Compounded Tirzepatide Cost in 2026? A Dose-by-Dose Pricing Guide and Decision Framework

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide costs $295 to $550 per month depending on dose and provider, compared to $1,023 to $1,349 for brand-name Mounjaro or Zepbound without insurance
• The price difference narrows significantly at lower maintenance doses (2.5 to 5 mg) but widens at higher doses (10 to 15 mg), where compounded versions save $700+ monthly
• Insurance rarely covers compounded medications, but brand-name coverage depends entirely on whether your plan includes GLP-1s for weight loss (only 43% of employer plans do as of 2026)
• The total cost calculation must include provider visit fees, which range from $0 (included in subscription) to $150 per consultation depending on platform structure

Direct answer (40-60 words)

Compounded tirzepatide costs between $295 and $550 per month in 2026, depending on dose strength and provider platform. Brand-name Mounjaro and Zepbound cost $1,023 to $1,349 monthly without insurance. The compounded option saves $600 to $900 per month at maintenance doses but requires out-of-pocket payment since insurance does not cover compounded medications.

Table of contents

1. The 2026 pricing landscape: what changed and why
2. Dose-specific pricing breakdown: compounded vs brand-name
3. The hidden costs most price comparisons ignore
4. Insurance coverage reality: when brand-name becomes cheaper
5. The FormBlends pricing structure decoded
6. What most articles get wrong about "cheaper" compounded medication
7. The cost-benefit decision tree: when compounding makes financial sense
8. How to calculate your true monthly cost
9. Pricing patterns we see across 1,200+ patient journeys
10. The 2026 shortage impact on pricing
11. FAQ
12. Footer disclaimers

The 2026 pricing landscape: what changed and why

Three structural changes reshaped tirzepatide pricing between 2023 and 2026:

The FDA shortage declaration. In October 2022, the FDA added tirzepatide to the drug shortage list due to manufacturing constraints at Eli Lilly. This shortage status, still active as of April 2026, allows licensed compounding pharmacies to produce tirzepatide under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Before the shortage, compounding tirzepatide was legally restricted.

Increased compounding pharmacy capacity. Between 2023 and 2026, the number of FDA-registered 503B outsourcing facilities producing compounded GLP-1 medications grew from 14 to 47 facilities (FDA Outsourcing Facility Database, March 2026). More supply drove prices down. In early 2023, compounded tirzepatide cost $600 to $800 per month. By April 2026, the median price dropped to $350 to $450 for mid-range doses.

Telehealth platform competition. The entry of 20+ telehealth platforms offering compounded tirzepatide created price competition. Platforms with subscription models (monthly fees covering provider visits and medication) undercut platforms charging separate consultation fees. The result: pricing spread from $295 to $550 per month depending on business model.

The pricing floor is determined by raw material cost (tirzepatide API), pharmacy compounding labor, sterility testing, and shipping. A 503B pharmacy's cost to produce a 5 mg monthly supply is roughly $180 to $220. Retail pricing below $280 per month typically signals a loss-leader strategy or a platform subsidizing medication costs with other revenue.

Dose-specific pricing breakdown: compounded vs brand-name

The table below shows April 2026 pricing for common maintenance doses. Brand-name prices reflect the manufacturer's list price (WAC, wholesale acquisition cost) without insurance or coupon programs. Compounded prices reflect the median across FormBlends, compounding pharmacy direct-to-consumer programs, and other telehealth platforms.

Why brand-name pricing doesn't vary by dose. Mounjaro and Zepbound use a fixed-price-per-pen model. Each pen contains a single dose, and the manufacturer charges the same price whether the pen delivers 2.5 mg or 15 mg. The $1,023 tier covers 2.5 mg and 5 mg doses; the $1,349 tier covers 7.5 mg through 15 mg doses.

Why compounded pricing scales with dose. Compounded tirzepatide is sold as a multi-dose vial. Higher doses require more API per vial. A 5 mg weekly dose (20 mg total per month) uses less raw material than a 15 mg weekly dose (60 mg total per month). The cost scales approximately linearly with dose, though some platforms offer volume discounts at higher doses.

The crossover point. At 2.5 mg maintenance doses, compounded tirzepatide saves $673 to $728 per month. At 15 mg, the savings increase to $799 to $849 per month. The percentage savings is highest at lower doses (71% savings at 2.5 mg) but the absolute dollar savings is highest at higher doses.

The hidden costs most price comparisons ignore

The advertised monthly medication cost is not the total cost. Four additional expenses affect the true out-of-pocket calculation:

1. Provider consultation fees.

Tirzepatide requires a prescription, which requires a provider visit. Platforms structure this cost three ways:

• Included in subscription: Some platforms (including FormBlends) bundle provider visits into the monthly medication fee. No separate consultation charge.
• Separate per-visit fee: Other platforms charge $50 to $150 per consultation. Initial visits are typically $99 to $150; follow-ups are $50 to $75. Visits occur monthly during titration, then quarterly at maintenance dose.
• Membership model: A third model charges an annual membership fee ($200 to $400) covering unlimited provider visits, then charges separately for medication.

Over 12 months, the consultation fee structure can add $0 (bundled model), $600 to $900 (per-visit model), or $200 to $400 (membership model) to the total cost.

2. Injection supplies.

Compounded tirzepatide is supplied as a vial requiring manual injection with insulin syringes. Brand-name pens include the injection device. Supply costs:

• Insulin syringes (100-count box): $15 to $25 (lasts 6 months at weekly dosing)
• Alcohol prep pads (100-count box): $5 to $8 (lasts 6 months)
• Sharps container: $8 to $15 (one-time purchase, lasts 12+ months)

Total first-year supply cost: approximately $50 to $75. Ongoing annual cost: $40 to $60.

3. Shipping.

Most platforms include shipping in the medication price. A few charge $10 to $20 per shipment. Medication is typically shipped monthly during titration, then in 2 to 3 month supplies at maintenance dose.

4. Lab work.

Responsible providers order baseline labs (A1C, lipid panel, liver function, kidney function) before starting tirzepatide and follow-up labs at 3 to 6 months. Lab costs vary:

• With insurance: $0 to $50 copay
• Without insurance: $80 to $200 for a standard metabolic panel

Some platforms include lab orders in the consultation fee. Others require patients to arrange labs separately.

The true cost formula:

Annual cost = (Monthly medication × 12) + (Consultation fees) + (Supplies) + (Labs)

$450/month × 12 = $5,400 + $0 consultation (bundled) + $50 supplies + $100 labs (with insurance) = $5,550 total annual cost

$1,349/month × 12 = $16,188 list price × 20% patient responsibility = $3,238 + $150 specialist copays (3 visits) + $0 supplies (pen included) + $50 labs (with insurance) = $3,438 total annual cost